JPRN-UMIN000007544已完成未知
Additional effects of moderate-dose fluticasone and salmeterol combination therapy on exacerbations and airflow limitations in patients with COPD in Japan - Additional effects of SFC in patients with COPD
Kyusyu Asthma & COPD Forum0 个研究点目标入组 1,008 人开始时间: 2012年3月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 1,008
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 40years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. other respiratory diseases 2. regular use of inhaled corticosteroids 3. regular use of inhaled and transdermal beta2 agonists 4. severe other orgen diseases 5. active malignancies
研究者
相似试验
已完成
不适用
Additional effects of moderate-dose fluticasone and salmeterol combination therapy on exacerbations and airflow limitations in patients with COPD in JapaCOPDJPRN-UMIN000003403Kyusyu Asthma & COPD Forum1,008
已完成
不适用
The effect of combination therapy of fluticasone furoate nasal spray with levocetirizine hydrochloride in patients with Japanese cedar pollinosis in an artificial exposure chamber(OHIO Chamber).Japanese cedar pollinosisJPRN-UMIN000006502ippon Medical School42
进行中（未招募）
1 期
Efficacy of Fluticasone Propionate associated With Salmeterol underwent allogeneic hematopoietic stem cell transplantatioBronchiolitis Obliterative Syndrome after hematopoietic stem cell transplantation (HSCT)..EUCTR2020-003010-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)243
进行中（未招募）
不适用
A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthmaChronic disease of the lungs characterized by airway inflammation,bonchoconstriction and increased airway responsiveness.MedDRA version: 16.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-003338-15-DEGlaxoSmithKline Research and Development Limited575
进行中（未招募）
不适用
A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthmaChronic disease of the lungs characterized by airway inflammation,bronchoconstriction and increased airway responsiveness.MedDRA version: 15.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-003338-15-SEGlaxoSmithKline Research and Development Limited575